Ipilimumab Pharmacotherapy in Patients with Metastatic Melanoma | Zendy

Joanne Jeter | Zendy; Lee D. Cranmer | Zendy; Evan M. Hersh | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ipilimumab Pharmacotherapy in Patients with Metastatic Melanoma

Author(s) -

Joanne Jeter,

Lee D. Cranmer,

Evan M. Hersh

Publication year - 2012

Publication title -

clinical medicine insights oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.601

H-Index - 26

ISSN - 1179-5549

DOI - 10.4137/cmo.s7245

Subject(s) - ipilimumab , medicine , metastatic melanoma , adverse effect , melanoma , oncology , clinical trial , drug , monoclonal antibody , pharmacotherapy , chemotherapy , immune system , immunotherapy , intensive care medicine , pharmacology , immunology , cancer , antibody , cancer research

Immune augmentation with ipilimumab, an anti-CTLA-4 monoclonal antibody, has joined the ranks of approved immunologic agents for the treatment of metastatic melanoma. Phase III studies of ipilimumab in metastatic melanoma have demonstrated an overall survival advantage as compared to other approved and investigational therapies. However, the adverse effects associated with this medication are unique and often require management with steroids or other immunosuppressants. In addition, the time to response differs with ipilimumab as compared to traditional chemotherapy, and alternative means of assessment of response have been proposed. In this review, we will summarize the basic science of this treatment, its preclinical evaluation, and the clinical trials leading to its approval. We will also discuss the details regarding its use, assessment of response to this drug and other immune-related therapies, and further directions for investigation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research